What Sales Managers Miss When They Only Track Activity in Field Teams

Most healthcare sales managers know, somewhere in the back of their mind, that their activity dashboards are not telling them the full story. Call counts look fine, in-service numbers are holding and yet certain territories stall, pipeline thins, and quota slips in ways that the data cannot explain.

The standard response is to push for more activity. That is usually the wrong diagnosis.

The problem is that activity metrics, on their own, measure the input without capturing whether the input is doing any useful work.

Salesforce’s State of Sales research found that sales reps spend only 28% of their week actually selling. The remaining 72% goes to admin, prep, internal meetings, and research. In healthcare field sales, where physician access has tightened considerably and HCPs are more selective about which companies they engage with, the quality of that 28% matters far more than any push to increase raw call volume.

The managers who outperform are not necessarily the ones with the most active teams. They are the ones who have learned to read past the activity number to what the activity is actually touching.

Why Activity Metrics Became the Default

The logic that built activity tracking into healthcare field sales was reasonable at the time. Prescription pulls and procedure volumes took weeks to settle at the territory level, and by the time they arrived, they were too blunt to coach against. Call reports, by contrast, were available the next morning.

So performance management systems built around what was fast and visible, and field teams calibrated their week around what was being counted.

There is an older structural reason too. About half of all sales forces have historically used activity-based incentive compensation tied to call reports. The underlying assumption was that call frequency correlates with prescription lift, so paying for calls would, by extension, pay for outcomes.

That assumption held reasonably well in a market where physician access was abundant, HCPs welcomed rep visits as a genuine source of clinical information, and the rep population was smaller relative to the physician base.

Those conditions have inverted. According to Veeva’s analysis of over 600 million HCP interactions annually from more than 80% of commercial biopharma field teams, HCP access dropped from 60% to 45% between 2022 and 2024 in the U.S., returning to pre-pandemic levels. Half of accessible HCPs now restrict engagement to three or fewer companies.

In specialties like oncology, internal medicine, and psychiatry, nearly 30% will engage with just one company. The window for influence has narrowed significantly, and yet most management systems still measure how often a rep knocks rather than whether the right doors are being knocked on.

The management infrastructure built around activity has outlasted the conditions that justified it. That is the gap most teams are operating inside.

The Problem with Measuring “More” Instead of “Better”

Pushing for higher call volume is the most common response to a territory that is not producing. It is also, in most cases, the wrong one. The issue is rarely that reps are not working hard enough. It is that the work is being pointed in the wrong direction, and the metrics in use cannot show that.

Reps Optimize for What Gets Counted

Activity management produces activity. That sounds obvious, but the downstream consequences are not always visible until after a territory has already underperformed.

Reps optimize for what gets counted and what gets coached. If a manager’s weekly review starts with call numbers, reps build their week around call numbers. That means shorter interactions, more stops in geographically convenient clusters, and a structural disincentive to spend ninety minutes with a high-value surgeon who is harder to reach.

Pharma incentive research frames this that poorly designed activity incentives distort call patterns and push field teams toward activity that looks busy but does not improve account quality. Reps are not gaming the system cynically. They are responding rationally to the signals they are being sent.

Activity Volume and Engagement Quality Are Not the Same Thing

The evidence from field engagement data makes the same point from the outcome side.

Veeva’s May 2025 Pulse analysis found that content-driven HCP engagement more than doubles treatment adoption. Yet field teams use approved content in fewer than half of all customer interactions, and nearly 80% of approved content is rarely or never used.

A call that hits the activity count without a substantive clinical exchange is, in aggregate, less likely to move the customer. Both calls score one on the dashboard.

PharmExec’s analysis of pharma sales force effectiveness quoted one general manager who put the structural problem as SFE metrics swinging up and down without any corresponding impact on the business.

The pharmaceutical industry spends $4 to $6 million annually on third-party research measuring rep-HCP interactions at many top companies, and the causal link between those interactions and commercial outcomes remains, in many programs, unestablished.

This is the defining limitation of activity-only management that it measures effort without establishing whether that effort is being directed at the right places, in the right ways, for the right reasons.

What Sales Managers Often Miss

The blind spots that activity tracking hides sit in plain sight. They persist because the dashboard has no column for them.

Target Quality: Who Is Actually on the List

A rep calling on twelve physicians a week, none of whom perform the relevant procedures at meaningful volume, will generate strong activity numbers and weak results.

A manager reviewing only call counts has no way to ask the prior question, whether the list was right before whether the effort was sufficient. In medical device sales, this is the most expensive mistake a field team can make.

Executing well against the wrong physicians wastes rep time, erodes HCP patience for future engagement, and produces a data trail that obscures the real problem.

Specialty label is not the same as billing behavior. A surgeon categorized as “orthopedic” may perform the relevant procedure five times a year or five hundred. Activity tracking does not distinguish between them. CPT-level billing data does.

Interaction Quality: What Actually Happened in the Call

A “call” can mean a sixty-second drop at the front desk or a forty-five-minute clinical conversation that moves a surgeon meaningfully closer to evaluation. Both count as one.

The Veeva data captures part of what gets missed here like content usage, meeting duration, and follow-up rate are all knowable. Virtual HCP interactions in the U.S. average 18 minutes, and physicians who engage through both in-person and video meet with companies 2.5 times more frequently than those who meet only in person.

These are signals about interaction quality that activity logs rarely capture in a form that makes a coaching conversation more useful.

Account-Level Structural Changes

A target physician may have billed steady volumes of the relevant procedure last year and shifted significantly this year because of a payer policy change, a hospital employment shift that restricts device choices, a change in their clinical focus, or retirement.

Activity logs record that the rep called. They do not record whether the underlying opportunity is the same size it was. A manager who does not check will spend coaching capital pushing for more touches on accounts that have become unviable, while the rep already knows.

As healthcare systems grew more complex and physician access more restricted, promotional volume stopped reflecting impact. The instinct to call more on any account in decline is often exactly backward.

The Accounts Not on the List at All

A territory’s growth rarely comes from working the current list harder. It comes from finding accounts the team did not know to prioritize. Market structure shifts can redistribute opportunity quickly.

CMS’s most recent rule additions moved hundreds of procedures from inpatient to outpatient ASC settings, opening fresh volume at surgical centers that field teams built around hospital relationships may not be covering at all.

Activity dashboards are bounded by the list the activity is being logged against. They have no mechanism for surfacing what is missing.

Understanding the Difference Between Activity and Effectiveness

Most management frameworks treat activity and effectiveness as points on the same scale. They are not. Activity is a count. Effectiveness is a judgment about whether the count produced anything worth counting.

Conflating the two is what allows a team to post strong numbers through a bad quarter.

The Three Layers Most Management Systems Miss

Activity describes what a rep does. Effectiveness describes what changes because of it. Most management systems own the first layer well, partially own outcomes with a lag, and barely touch what sits between the two, which is engagement quality.
A clean framework separates three layers. Activity covers calls completed, in-services delivered, samples dropped. Engagement quality covers content used, interaction depth, follow-up kept. Outcomes cover procedure volume change, share in target accounts, conversion to orders, revenue per call.

Without the middle layer, a manager looking at a low-growth territory cannot diagnose whether the problem is too little activity, the wrong activity, or activity reaching the right physicians in the wrong way. Without that diagnosis, the default intervention is volume. Volume is rarely the answer.

From Effort Measurement to Influence Measurement

Everstage’s pharma sales effectiveness analysis frames the distinction that activity metrics capture effort but not influence. They tell you who is busy.

The leading pharma organizations have moved toward a blended model where execution data sits alongside outcome data, rather than substituting for it. The shift is less about adding metrics than about changing which question the weekly review is actually answering.

Improving Performance Conversations with Better Context

The performance conversation is where activity-only management does the most damage, in ways that compound quietly over time.

A review centered on call counts produces one kind of coaching, more calls, faster calls, broader coverage. A review centered on the fit between rep effort and account potential produces a different kind of coaching and, over time, a different kind of rep.

Three changes make the conversation more useful without requiring a full management system overhaul.

Build Account Context into the Review

The most useful version of a territory review starts one level up from the activity:

• What is the actual procedure volume in the rep’s top-priority accounts
• How has it trended
• What has changed in the accounts that are not moving

Knowing that a particular surgeon has billed 280 of the relevant CPT codes in the last twelve months and that the rep has not yet had a clinical conversation about the adjacent indication is a completely different coaching anchor.

CPT-level billing data is the ground truth a coaching conversation needs. It replaces the implicit assumption that all accounts on a list are roughly equivalent, which they almost never are.

Separate Territory Structure from Rep Execution

Two territories with identical call numbers can be producing completely different results because of differences in account density, geographic spread, physician accessibility by specialty, and the proportion of target accounts locked into competitor contracts.

A manager who does not account for territory structure when evaluating rep performance is making a fairness error and a strategic one. Activity data does not surface this. Procedure volume mapped to geography does.

Make Account-Level Stagnation the Central Conversation

Instead of “did you hit your call number,” the more useful question is, which of your top fifteen accounts moved this month, and what is the specific plan for the ones that did not. Most reps know which accounts are stuck and why.

Activity-led reviews give them no space to say so. Account-level reviews force the trade-offs into the open, including the legitimate ones, a high-priority account locked into a competing contract that no amount of additional calls will move this quarter.

Identifying Patterns That Activity Metrics Hide

The patterns that matter most to a sales manager become visible only when activity data is overlaid with account-level and market-level context. Several are worth looking for specifically.

High Activity, Low Conversion

A rep with strong call numbers and weak progression in target accounts is almost always working the wrong list, or working the right list with the wrong message.

Pushing for more activity makes the problem worse. The right intervention is to audit the list against current procedure volume before changing anything.

Low Activity, Strong Conversion

Easy to celebrate quickly and worth examining just as carefully. A territory posting revenue without proportionate activity may be riding a single large account or a one-time tailwind. The question is whether the success is repeatable and what it would take to build more of it deliberately.

Coverage Gaps Inside the List

Activity logs aggregate well at the rep level and hide systematic gaps at the account level. A rep hitting their weekly call number may be consistently deprioritizing the top quartile of target accounts because those physicians are harder to access.

Account-level coverage analysis surfaces this pattern. Activity totals do not.

Stale Account Quality

A target physician who anchored a territory in 2024 may now be employed by a health system that restricts rep access, have shifted procedure focus, or have retired.

Without a refresh against current billing data, the rep keeps calling, the manager keeps counting, and the territory quietly bleeds opportunity.

Missed Market Movement

The EY Pulse of the MedTech Industry 2025 report frames the commercial environment clearly, a $584 billion industry at 6 to 7% revenue growth, with investors increasingly distinguishing companies that achieve commercial efficiency from those that scale activity.

McKinsey’s commercial capabilities research across more than 60 MedTech companies found that those with the most advanced commercial capabilities grew at a CAGR 1.4 times higher than companies with average capabilities. The companies pulling ahead are doing so by targeting more precisely, not by adding more calls.

How Alpha Sophia Helps Move Beyond Activity Tracking

The reason activity tracking dominates is that it is the data most managers have. The reason effectiveness measurement is harder is that it requires a different data foundation, one built on physician-level billing evidence rather than rep-level call logs.

Targeting Built on Billing Behavior, Not Specialty Label

Alpha Sophia draws from approximately 80% of U.S. medical claims across Medicare, Medicaid, and commercial payors, with filtering by CPT, HCPCS, ICD-10, and taxonomy.

For a sales manager, that translates into something specific. Every physician on a rep’s target list can be evaluated against actual billing behavior, not specialty labels.

A territory built with Alpha Sophia does not call on “orthopedic surgeons in the northeast corridor.” It calls on the orthopedic surgeons whose billing history shows consistent volume in the procedures the device addresses, ranked by that volume, with geography factored in.

The difference between those two lists is where most of the performance gap lives.

Territory Design That Reflects Real Opportunity

The Territory Manager closes a second gap between analytically sound targeting and plans the field can actually execute.

Managers can build, edit, and manage territories nationwide directly in the platform, with driving distance calculated in miles so proximity is a real input rather than an assumption.

Opportunity size is visible in the same workflow as territory boundaries, so the decision about where to draw a line is never made without knowing what sits on each side of it.

That principle, and how it changes the way reps prioritize accounts week to week, is covered in depth in Alpha Sophia’s territory planning guide for healthcare sales reps.

Cohort Analysis and CRM Integration

Cohort analysis lets sales leaders compare groups of physicians across procedure volume, specialty, geography, and affiliation, tracking how those patterns shift over time. That is precisely the capability that surfaces stale account quality and emerging market movement before they show up as a missed quarter.

The recently available Alpha Sophia API, together with native HubSpot integrations, means the provider-level data does not have to live separately from the CRM where activity is logged. A manager reviewing the week can see rep effort and account potential side by side.

The data does not replace the manager’s judgment. It gives the performance conversation a foundation that activity-only dashboards cannot.

Conclusion

Tracking field sales activity is not the mistake. The mistake is treating it as sufficient. In a market where physician access is contracting, HCPs are more selective, and commercial efficiency has become a competitive differentiator, the distance between a rep who is busy and a rep who is effective can be enormous.

The dashboard does not show that distance. Claims data does.

Getting the underlying account intelligence right is what turns activity reviews into actual performance management. That is the shift worth building toward, and it starts well before any conversation about call frequency.

FAQs

Why are activity metrics not enough in field sales?
Activity metrics record what a rep did, not whether it worked. In healthcare, where physician access is limited and HCPs restrict engagement to a small number of companies, the quality and targeting of each interaction matters far more than raw call volume. Activity counts alone cannot distinguish between a rep calling on the right physicians and a rep generating movement.

What is the difference between activity and performance in sales?
Activity is input. Performance is output like procedure volume growth in target accounts, conversion to orders, market share in a territory. A healthy performance system measures both, with outcomes weighted more heavily. Activity without outcome context is incomplete.

What do sales managers miss when tracking only activity?
Four things consistently, whether the target list is accurate at the billing-behavior level, whether interactions are substantive enough to drive clinical change, whether accounts have structurally changed in ways that affect their viability, and whether new high-value accounts have emerged outside the current list.

How can managers measure field sales effectiveness?
By combining three layers of data, activity from the CRM, engagement quality signals like content used and meeting duration, and outcome data tied to physician-level billing evidence at each account. That combination supports both coaching and accountability in ways that activity tracking alone cannot.

Why do high activity levels not always lead to results?
Because activity is bounded by the target list and the quality of each interaction. A rep working hard on the wrong accounts, or reaching the right accounts with generic messaging in a market where HCPs are being highly selective about who they engage with, will post strong activity numbers and weak outcomes.

What are common blind spots in sales performance tracking?
Stale target lists that no longer reflect current billing behavior, coverage gaps inside the list where high-priority accounts get deprioritized, structural changes inside accounts that make them less viable, and market movement like procedure migration to new care settings that sits entirely outside the current call plan.